期刊文献+

尼妥珠单抗联合顺铂和氟尿嘧啶治疗头颈部鳞癌的临床疗效分析 被引量:2

暂未订购
导出
摘要 目的观察采用尼妥珠单抗联合顺铂和氟尿嘧啶治疗头颈部鳞癌的临床疗效和不良反应,为临床安全用药提供合理依据。方法选取我院2010年7月至2012年7月间收治的138例头颈部鳞癌患者,随机分为治疗组和对照组,每组69例。治疗组69例头颈部鳞癌患者采用尼妥珠单抗联合顺铂和氟尿嘧啶进行治疗与对照组69例头颈部鳞癌患者采用氟尿嘧啶进行治疗,并比较观察各组的疗效和不良反应。结果治疗组69例头颈部鳞癌患者中,完全缓解41例(59.42%),总有效率为89.85%;对照组69例患者中,完全缓解28例(40.58%),总有效率为69.57%。可见,治疗组的疗效明显优于对照组,经统计学处理,P<0.05,疗效差异显著,具有统计学意义。结论本组治疗组所采用的尼妥珠单抗联合顺铂和氟尿嘧啶头颈部鳞癌的治疗方法较对照组的氟尿嘧啶治疗头颈部鳞癌的方法具有显著的疗效,毒副反应比较小,所以值得在临床上进行推广应用。
作者 赵京红 孙欣
机构地区 吉林省肿瘤医院
出处 《中国医药指南》 2013年第14期645-646,共2页 Guide of China Medicine
  • 相关文献

参考文献2

  • 1罗京伟,徐国镇.鼻咽癌治疗的进展[J].中华耳鼻咽喉科杂志,2004,39(8):509-512. 被引量:47
  • 2唐平章.下咽癌的手术方式和综合治疗[J].中华耳鼻咽喉科杂志,2009,34(27):17219.

二级参考文献22

  • 1屠规益 汪磊.医师需要还是患者需要[J].中华耳鼻咽喉科杂志,1999,34:326-327.
  • 2Xiao J, Xu G, Miao Y. Fractionated stereotactic radiotherapy for 50 patients with recurrent or residual nasopharyngeal carcinoma. Int J Rad Oncol Biol Phys, 2001,51:164-170.
  • 3Le QT, Tate D, Koong A, et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 2003,56:1046-1054.
  • 4Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensitymodulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys, 2000, 48:711-722.
  • 5Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of USCF experience. Int J Radiat Oncol Biol Phys, 2002, 53:12-22.
  • 6Eisbruch A, Kim HM,Terrell JE,et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2001, 50:695-724.
  • 7Kwong DL, Pow E, McMillan A, et al. Intensity-modulated radiotherapy for early stage nasopharyngeal carcinoma: preliminary results on parotid sparing. 2003,57 Suppl 2:s303.
  • 8Shu CH, Cheng H, Limg JF, et al. Salvage surgery for recurrent nasopharyngeal carcinoma. Laryngoscope, 2000,110:1483-1488.
  • 9King WW, Ku PK, Mok C, et al. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience. Head Neck ,2000,22:215-222.
  • 10International nasopharynx cancer study group. Preliminary results of a randomized trial comparing neoadjurant chemotherapy (cisplatin,epirubicin, bleomycin)plus radiotherapy vs. radiotherapy alone in satge Ⅳ( ≥ N2M0) undifferentiated nasopharyngeal carc

共引文献46

同被引文献25

  • 1SCHMITZ S,ANG K K,VERMORKEN J,et al.Targeted therapies for squamous cell carcinoma of the head and neck:current knowledge and future directions[J].Cancer Treat Rev,2014,40:390-404.
  • 2MOHER D,LIBERATI A,TETZLAFF J,et al.Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J].BMJ,2009,339:b2535-b2535.
  • 3JADAD A R,MOORE R A,CARROLL D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary[J]?Control Clin Trials,1996,17:1-12.
  • 4PARMAR M K,TORRI V,STEWART L.Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J].Stat Med,1998,17:2815-2834.
  • 5HIGGINS J P,THOMPSON S G,DEEKS J J,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327:557-560.
  • 6DERSIMONIAN R,LAIRD N.Meta-analysis in clinical trials[J].Control Clin Trials,1986,7:177-188.
  • 7BONNER J A,HARARI P M,GIRALT J,et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J].N Engl J Med,2006,354:567-578.
  • 8BONNER J A,HARARI P M,GIRALT J,et al.Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer:5-year survival data from a phase 3randomised trial,and relation between cetuximab-induced rash and survival[J].Lancet Oncol,2010,11:21-28.
  • 9RAMAKRISHNAN M S,ESWARAIAH A,CROMBET T,et al.Nimotuzumab,apromising therapeutic monoclonal for treatment of tumors of epithelial origin[J].MAbs,2009,1:41-48.
  • 10REDDY B K,LOKESH V,VIDYASAGAR M S,et al.Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck:a randomized,open-label,phase IIb,5-year study in Indian patients[J].Oral Oncol,2014,50:498-505.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部